The drug belongs to a class of medications known as PARP inhibitors, which help block what is left of the DNA repair mechanism so cancer cells are unable to replicate and a tumor cannot sustain itself.
The drug is approved as a first-line maintenance therapy for adult patients with BRCA-mutated pancreatic adenocarcinoma whose disease has spread beyond the pancreas and whose tumors didn’t worsen after 16 weeks of chemotherapy.
Lynparaza, manufactured by AstraZeneca and Merck, already is approved for ovarian and breast cancers.
More articles on pharmacy:
Drugmakers shift from clinical trials, mine EMRs for drug approvals
Roche buys international rights to Sarepta’s Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.